The Board of Directors of the Shanghai Henlius Biotech, Inc. announced that the application for phase 1b/2 clinical trial for HLX208 (BRAF V600E inhibitor) ("HLX208") monotherapy or in combination therapy for the treatment of BRAF V600E or BRAF V600 mutation-positive advanced solid tumours has recently been approved by the National Medical Products Administration ("NMPA"). The Company intends to conduct clinical trials for the relevant indications of the product in China (excluding Hong Kong, Macau and Taiwan regions, the same below) when the conditions are satisfied.